Clinical Trials Browser

Completed × Ovarian Neoplasms × NVP-BKM120 × Clear all

NCT01623349 2021-02-10

Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer

Phase 1 Completed

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms, Recurrence

NCT01068483 2020-12-08

Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients

Phase 1 Completed

BreastGastrointestinalGynecologic

Breast Neoplasms, Colonic Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT01363232 2020-10-05

Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients

Phase 1 Completed

BreastGastrointestinalGynecologic

Ovarian Neoplasms, Pancreatic Neoplasms, Triple Negative Breast Neoplasms